Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.

    Research output: Contribution to journalArticlepeer-review

    175 Citations (Scopus)

    Fingerprint Dive into the research topics of 'Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.'. Together they form a unique fingerprint.

    Medicine & Life Sciences